UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The chronic myeloid leukemia stem cell: stemming the tide of persistence

Blood, 2017-03, Vol.129 (12), p.1595-1606

2017

Volltextzugriff (PDF)

Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells

Nature medicine, 2017-10, Vol.23 (10), p.1234-1240

2017

Volltextzugriff (PDF)

Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor–treated CML stem cells

Blood, 2016-12, Vol.128 (23), p.2671-2682

2016

Volltextzugriff (PDF)

Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia

Blood, 2014-06, Vol.123 (25), p.3951-3962

2014

Volltextzugriff (PDF)

Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells

Nature (London), 2016-06, Vol.534 (7607), p.341-346

2016

Volltextzugriff (PDF)

CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy

Leukemia, 2020-06, Vol.34 (6), p.1613-1625

2020

Volltextzugriff (PDF)

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

The Journal of clinical investigation, 2013-10, Vol.123 (10), p.4144-4157

2013

Volltextzugriff (PDF)

Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition

Cancer discovery, 2016-11, Vol.6 (11), p.1248-1257

2016

Volltextzugriff (PDF)

CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression

Blood, 2017-01, Vol.129 (2), p.199-208

2017

Volltextzugriff (PDF)

Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells

Blood, 2013-05, Vol.121 (20), p.4175-4183

2013

Volltextzugriff (PDF)

Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606

Blood, 2008-02, Vol.111 (4), p.2329-2338

2008

Volltextzugriff (PDF)

The Antiproliferative Activity of Kinase Inhibitors in Chronic Myeloid Leukemia Cells Is Mediated by FOXO Transcription Factors

Stem cells (Dayton, Ohio), 2014-09, Vol.32 (9), p.2324-2337

2014

Volltextzugriff (PDF)

Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML

Clinical cancer research, 2016-04, Vol.22 (8), p.2051-2061

2016

Volltextzugriff (PDF)

hsa-mir183/EGR1–mediated regulation of E2F1 is required for CML stem/progenitor cell survival

Blood, 2018-04, Vol.131 (14), p.1532-1544

2018

Volltextzugriff (PDF)

Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks

The Journal of experimental medicine, 2011-10, Vol.208 (11), p.2155-2158

2011

Volltextzugriff (PDF)

Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1―BCR-ABL―JAK2 Complex

JNCI : Journal of the National Cancer Institute, 2013-03, Vol.105 (6), p.405-423

2013

Volltextzugriff (PDF)

Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells

Cancer research (Chicago, Ill.), 2008-12, Vol.68 (23), p.9624-9633

2008

Volltextzugriff (PDF)

Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate

Blood, 2006-08, Vol.108 (4), p.1370-1373

2006

Volltextzugriff (PDF)

Autophagy in blood cancers: biological role and therapeutic implications

Haematologica (Roma), 2013-09, Vol.98 (9), p.1335-1343

2013

Volltextzugriff (PDF)

Autophagy in chronic myeloid leukaemia: stem cell survival and implication in therapy

Current cancer drug targets, 2013-09, Vol.13 (7), p.724-734

2013

Volltextzugriff (PDF)

Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt–β-catenin signaling

Blood, 2013-03, Vol.121 (10), p.1824-1838

2013

Volltextzugriff (PDF)

Stem Cell Guardians - Old and New Perspectives in LSC Biology

Current drug targets, 2017-01, Vol.18 (4), p.405-413

2017

Volltextzugriff (PDF)

Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia

Haematologica (Roma), 2010-02, Vol.95 (2), p.224-231

2010

Volltextzugriff (PDF)

1 – 25 von 112

Suche als RSS-Feed

Aktive Filter

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(109)
Mit Volltextzugriff
(99)

Publikationsform

Artikel
(112)

Sprache

Englisch
(112)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The chronic myeloid leukemia stem cell: stemming the tide of persistence

Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells

Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor–treated CML stem cells

Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia

Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells

CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy

Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition

CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression

Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells

Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606

The Antiproliferative Activity of Kinase Inhibitors in Chronic Myeloid Leukemia Cells Is Mediated by FOXO Transcription Factors

Rac2-MRC-cIII–generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors

Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML

hsa-mir183/EGR1–mediated regulation of E2F1 is required for CML stem/progenitor cell survival

Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks

Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1―BCR-ABL―JAK2 Complex

Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells

Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate

Autophagy in blood cancers: biological role and therapeutic implications

Autophagy in chronic myeloid leukaemia: stem cell survival and implication in therapy

Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt–β-catenin signaling

Stem Cell Guardians - Old and New Perspectives in LSC Biology

Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia

Aktive Filter

Suchergebnisse filtern